nodes	percent_of_prediction	percent_of_DWPC	metapath
Topiramate—CA5B—Hydrochlorothiazide—nephrolithiasis	0.169	0.201	CbGbCtD
Topiramate—CA12—Hydrochlorothiazide—nephrolithiasis	0.145	0.173	CbGbCtD
Topiramate—CA9—Hydrochlorothiazide—nephrolithiasis	0.145	0.173	CbGbCtD
Topiramate—CA1—Hydrochlorothiazide—nephrolithiasis	0.136	0.162	CbGbCtD
Topiramate—CA4—Hydrochlorothiazide—nephrolithiasis	0.128	0.152	CbGbCtD
Topiramate—CA2—Hydrochlorothiazide—nephrolithiasis	0.118	0.14	CbGbCtD
Topiramate—Panic disorder—Hydrochlorothiazide—nephrolithiasis	0.00869	0.0865	CcSEcCtD
Topiramate—CA2—collecting duct of renal tubule—nephrolithiasis	0.00609	0.179	CbGeAlD
Topiramate—GRIK4—renal system—nephrolithiasis	0.00449	0.132	CbGeAlD
Topiramate—GRIK4—kidney—nephrolithiasis	0.00434	0.128	CbGeAlD
Topiramate—CA4—Erythrocytes take up carbon dioxide and release oxygen—AQP1—nephrolithiasis	0.0038	0.159	CbGpPWpGaD
Topiramate—CA2—Erythrocytes take up carbon dioxide and release oxygen—AQP1—nephrolithiasis	0.00364	0.152	CbGpPWpGaD
Topiramate—CA1—Erythrocytes take up carbon dioxide and release oxygen—AQP1—nephrolithiasis	0.00349	0.146	CbGpPWpGaD
Topiramate—GRIK5—cortex of kidney—nephrolithiasis	0.00308	0.0908	CbGeAlD
Topiramate—CYP2C19—urine—nephrolithiasis	0.00237	0.0699	CbGeAlD
Topiramate—Intraocular pressure increased—Hydrochlorothiazide—nephrolithiasis	0.00228	0.0227	CcSEcCtD
Topiramate—Leg pain—Hydrochlorothiazide—nephrolithiasis	0.00217	0.0216	CcSEcCtD
Topiramate—Raised liver function tests—Hydrochlorothiazide—nephrolithiasis	0.00217	0.0216	CcSEcCtD
Topiramate—Sinus bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00204	0.0203	CcSEcCtD
Topiramate—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.00204	0.0203	CcSEcCtD
Topiramate—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.0019	0.019	CcSEcCtD
Topiramate—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00179	0.0178	CcSEcCtD
Topiramate—Toothache—Hydrochlorothiazide—nephrolithiasis	0.00165	0.0164	CcSEcCtD
Topiramate—CA7—renal system—nephrolithiasis	0.00159	0.047	CbGeAlD
Topiramate—Encephalopathy—Hydrochlorothiazide—nephrolithiasis	0.00156	0.0155	CcSEcCtD
Topiramate—CA7—kidney—nephrolithiasis	0.00154	0.0454	CbGeAlD
Topiramate—CYP3A4—urine—nephrolithiasis	0.0014	0.0413	CbGeAlD
Topiramate—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.00139	0.0138	CcSEcCtD
Topiramate—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00128	0.0127	CcSEcCtD
Topiramate—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00122	0.0121	CcSEcCtD
Topiramate—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.00116	0.0115	CcSEcCtD
Topiramate—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00112	0.0111	CcSEcCtD
Topiramate—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00111	0.011	CcSEcCtD
Topiramate—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00108	0.0108	CcSEcCtD
Topiramate—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00105	0.0104	CcSEcCtD
Topiramate—CA12—renal system—nephrolithiasis	0.00104	0.0305	CbGeAlD
Topiramate—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00102	0.0102	CcSEcCtD
Topiramate—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00101	0.0101	CcSEcCtD
Topiramate—CA12—kidney—nephrolithiasis	0.001	0.0295	CbGeAlD
Topiramate—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.000915	0.00911	CcSEcCtD
Topiramate—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.000905	0.00902	CcSEcCtD
Topiramate—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00084	0.00836	CcSEcCtD
Topiramate—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.000836	0.00832	CcSEcCtD
Topiramate—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.000828	0.00825	CcSEcCtD
Topiramate—CA1—renal system—nephrolithiasis	0.00082	0.0242	CbGeAlD
Topiramate—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00082	0.00817	CcSEcCtD
Topiramate—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.000812	0.00809	CcSEcCtD
Topiramate—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.000798	0.00795	CcSEcCtD
Topiramate—CA1—kidney—nephrolithiasis	0.000793	0.0234	CbGeAlD
Topiramate—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.000784	0.00781	CcSEcCtD
Topiramate—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.000777	0.00774	CcSEcCtD
Topiramate—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.000774	0.00771	CcSEcCtD
Topiramate—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00077	0.00767	CcSEcCtD
Topiramate—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.000767	0.00764	CcSEcCtD
Topiramate—Thirst—Hydrochlorothiazide—nephrolithiasis	0.000764	0.00761	CcSEcCtD
Topiramate—Purpura—Hydrochlorothiazide—nephrolithiasis	0.000754	0.00751	CcSEcCtD
Topiramate—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00073	0.00727	CcSEcCtD
Topiramate—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.000727	0.00724	CcSEcCtD
Topiramate—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.000721	0.00718	CcSEcCtD
Topiramate—Migraine—Hydrochlorothiazide—nephrolithiasis	0.000715	0.00713	CcSEcCtD
Topiramate—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.000715	0.00713	CcSEcCtD
Topiramate—CA4—nephron tubule—nephrolithiasis	0.000705	0.0208	CbGeAlD
Topiramate—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.000702	0.00699	CcSEcCtD
Topiramate—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.000689	0.00686	CcSEcCtD
Topiramate—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.000683	0.00681	CcSEcCtD
Topiramate—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.000681	0.00678	CcSEcCtD
Topiramate—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.000671	0.00668	CcSEcCtD
Topiramate—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.000664	0.00661	CcSEcCtD
Topiramate—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.000664	0.00661	CcSEcCtD
Topiramate—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.000661	0.00659	CcSEcCtD
Topiramate—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.000657	0.00654	CcSEcCtD
Topiramate—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000654	0.00652	CcSEcCtD
Topiramate—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.000654	0.00652	CcSEcCtD
Topiramate—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.000643	0.00641	CcSEcCtD
Topiramate—CA4—renal system—nephrolithiasis	0.000641	0.0189	CbGeAlD
Topiramate—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000641	0.00639	CcSEcCtD
Topiramate—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.000641	0.00639	CcSEcCtD
Topiramate—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.000632	0.0063	CcSEcCtD
Topiramate—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.000628	0.00626	CcSEcCtD
Topiramate—CA4—kidney—nephrolithiasis	0.00062	0.0183	CbGeAlD
Topiramate—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.000616	0.00614	CcSEcCtD
Topiramate—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.000612	0.0061	CcSEcCtD
Topiramate—CA4—cortex of kidney—nephrolithiasis	0.000604	0.0178	CbGeAlD
Topiramate—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.000587	0.00585	CcSEcCtD
Topiramate—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.000587	0.00585	CcSEcCtD
Topiramate—CA2—nephron tubule—nephrolithiasis	0.000585	0.0172	CbGeAlD
Topiramate—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.000584	0.00582	CcSEcCtD
Topiramate—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00058	0.00578	CcSEcCtD
Topiramate—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.000579	0.00576	CcSEcCtD
Topiramate—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.000573	0.00571	CcSEcCtD
Topiramate—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.000572	0.00569	CcSEcCtD
Topiramate—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.000567	0.00564	CcSEcCtD
Topiramate—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.000563	0.00561	CcSEcCtD
Topiramate—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.000555	0.00553	CcSEcCtD
Topiramate—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.000551	0.00548	CcSEcCtD
Topiramate—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.000549	0.00547	CcSEcCtD
Topiramate—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.000544	0.00542	CcSEcCtD
Topiramate—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.000544	0.00542	CcSEcCtD
Topiramate—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.000534	0.00532	CcSEcCtD
Topiramate—CA2—renal system—nephrolithiasis	0.000532	0.0157	CbGeAlD
Topiramate—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.000528	0.00526	CcSEcCtD
Topiramate—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.000525	0.00523	CcSEcCtD
Topiramate—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.000523	0.00521	CcSEcCtD
Topiramate—CA2—kidney—nephrolithiasis	0.000514	0.0151	CbGeAlD
Topiramate—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.000512	0.0051	CcSEcCtD
Topiramate—GABRB2—Ion channel transport—CLCN4—nephrolithiasis	0.000507	0.0211	CbGpPWpGaD
Topiramate—GABRB2—Ion channel transport—CLCN5—nephrolithiasis	0.000507	0.0211	CbGpPWpGaD
Topiramate—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.000504	0.00502	CcSEcCtD
Topiramate—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.000503	0.00501	CcSEcCtD
Topiramate—CA2—cortex of kidney—nephrolithiasis	0.000501	0.0148	CbGeAlD
Topiramate—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.0005	0.00498	CcSEcCtD
Topiramate—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.000499	0.00497	CcSEcCtD
Topiramate—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.000495	0.00493	CcSEcCtD
Topiramate—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.000485	0.00483	CcSEcCtD
Topiramate—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.000475	0.00474	CcSEcCtD
Topiramate—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.000469	0.00467	CcSEcCtD
Topiramate—Flushing—Hydrochlorothiazide—nephrolithiasis	0.000467	0.00465	CcSEcCtD
Topiramate—GABRG2—Ion channel transport—CLCN4—nephrolithiasis	0.000463	0.0193	CbGpPWpGaD
Topiramate—GABRG2—Ion channel transport—CLCN5—nephrolithiasis	0.000463	0.0193	CbGpPWpGaD
Topiramate—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.000444	0.00443	CcSEcCtD
Topiramate—Erythema—Hydrochlorothiazide—nephrolithiasis	0.000438	0.00436	CcSEcCtD
Topiramate—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.000431	0.0043	CcSEcCtD
Topiramate—Tension—Hydrochlorothiazide—nephrolithiasis	0.00043	0.00428	CcSEcCtD
Topiramate—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000429	0.00427	CcSEcCtD
Topiramate—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.000425	0.00423	CcSEcCtD
Topiramate—Back pain—Hydrochlorothiazide—nephrolithiasis	0.000423	0.00422	CcSEcCtD
Topiramate—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.000421	0.00419	CcSEcCtD
Topiramate—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.000412	0.00411	CcSEcCtD
Topiramate—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00041	0.00409	CcSEcCtD
Topiramate—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.000406	0.00405	CcSEcCtD
Topiramate—GABRA1—Ion channel transport—CLCN5—nephrolithiasis	0.000405	0.0169	CbGpPWpGaD
Topiramate—GABRA1—Ion channel transport—CLCN4—nephrolithiasis	0.000405	0.0169	CbGpPWpGaD
Topiramate—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.000405	0.00403	CcSEcCtD
Topiramate—Agitation—Hydrochlorothiazide—nephrolithiasis	0.000402	0.00401	CcSEcCtD
Topiramate—Malaise—Hydrochlorothiazide—nephrolithiasis	0.000395	0.00393	CcSEcCtD
Topiramate—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.000393	0.00392	CcSEcCtD
Topiramate—Syncope—Hydrochlorothiazide—nephrolithiasis	0.000393	0.00391	CcSEcCtD
Topiramate—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.000392	0.0039	CcSEcCtD
Topiramate—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000387	0.00385	CcSEcCtD
Topiramate—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000385	0.00383	CcSEcCtD
Topiramate—Cough—Hydrochlorothiazide—nephrolithiasis	0.000382	0.0038	CcSEcCtD
Topiramate—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.000373	0.00371	CcSEcCtD
Topiramate—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.000373	0.00371	CcSEcCtD
Topiramate—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.000373	0.00371	CcSEcCtD
Topiramate—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.000371	0.0037	CcSEcCtD
Topiramate—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.000368	0.00367	CcSEcCtD
Topiramate—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000364	0.00363	CcSEcCtD
Topiramate—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00036	0.00359	CcSEcCtD
Topiramate—Oedema—Hydrochlorothiazide—nephrolithiasis	0.000357	0.00356	CcSEcCtD
Topiramate—Shock—Hydrochlorothiazide—nephrolithiasis	0.000351	0.0035	CcSEcCtD
Topiramate—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00035	0.00348	CcSEcCtD
Topiramate—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000349	0.00347	CcSEcCtD
Topiramate—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.000345	0.00344	CcSEcCtD
Topiramate—CYP3A4—renal system—nephrolithiasis	0.000343	0.0101	CbGeAlD
Topiramate—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.000341	0.00339	CcSEcCtD
Topiramate—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.000334	0.00333	CcSEcCtD
Topiramate—CYP3A4—kidney—nephrolithiasis	0.000332	0.00977	CbGeAlD
Topiramate—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000325	0.00324	CcSEcCtD
Topiramate—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000323	0.00322	CcSEcCtD
Topiramate—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.000321	0.0032	CcSEcCtD
Topiramate—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000318	0.00317	CcSEcCtD
Topiramate—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000318	0.00316	CcSEcCtD
Topiramate—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000314	0.00313	CcSEcCtD
Topiramate—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000311	0.00309	CcSEcCtD
Topiramate—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000308	0.00307	CcSEcCtD
Topiramate—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000305	0.00304	CcSEcCtD
Topiramate—Pain—Hydrochlorothiazide—nephrolithiasis	0.000305	0.00304	CcSEcCtD
Topiramate—GRIA3—BDNF signaling pathway—SPP1—nephrolithiasis	0.000301	0.0125	CbGpPWpGaD
Topiramate—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000294	0.00293	CcSEcCtD
Topiramate—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000292	0.00291	CcSEcCtD
Topiramate—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000284	0.00283	CcSEcCtD
Topiramate—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000282	0.00281	CcSEcCtD
Topiramate—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.000282	0.00281	CcSEcCtD
Topiramate—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000263	0.00262	CcSEcCtD
Topiramate—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000256	0.00255	CcSEcCtD
Topiramate—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000253	0.00252	CcSEcCtD
Topiramate—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000244	0.00243	CcSEcCtD
Topiramate—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000236	0.00235	CcSEcCtD
Topiramate—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000227	0.00226	CcSEcCtD
Topiramate—Rash—Hydrochlorothiazide—nephrolithiasis	0.000225	0.00224	CcSEcCtD
Topiramate—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000225	0.00224	CcSEcCtD
Topiramate—Headache—Hydrochlorothiazide—nephrolithiasis	0.000224	0.00223	CcSEcCtD
Topiramate—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000212	0.00211	CcSEcCtD
Topiramate—GRIA1—BDNF signaling pathway—SPP1—nephrolithiasis	0.00018	0.00751	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000176	0.00735	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000176	0.00735	CbGpPWpGaD
Topiramate—CA5A—Metabolism—GRHPR—nephrolithiasis	0.000165	0.00687	CbGpPWpGaD
Topiramate—CA6—Metabolism—GRHPR—nephrolithiasis	0.000165	0.00687	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000161	0.00673	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000161	0.00673	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000157	0.00656	CbGpPWpGaD
Topiramate—CA7—Metabolism—GRHPR—nephrolithiasis	0.000154	0.00642	CbGpPWpGaD
Topiramate—CA5B—Metabolism—GRHPR—nephrolithiasis	0.000154	0.00642	CbGpPWpGaD
Topiramate—CA6—Metabolism—AGXT—nephrolithiasis	0.000147	0.00613	CbGpPWpGaD
Topiramate—CA5A—Metabolism—AGXT—nephrolithiasis	0.000147	0.00613	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000144	0.006	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000144	0.006	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000144	0.006	CbGpPWpGaD
Topiramate—CA12—Metabolism—GRHPR—nephrolithiasis	0.000143	0.00595	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000141	0.00588	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000141	0.00588	CbGpPWpGaD
Topiramate—CA7—Metabolism—AGXT—nephrolithiasis	0.000137	0.00572	CbGpPWpGaD
Topiramate—CA5B—Metabolism—AGXT—nephrolithiasis	0.000137	0.00572	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000131	0.00548	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000131	0.00548	CbGpPWpGaD
Topiramate—CA12—Metabolism—AGXT—nephrolithiasis	0.000127	0.0053	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—SPP1—nephrolithiasis	0.000126	0.00525	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000126	0.00524	CbGpPWpGaD
Topiramate—CA6—Metabolism—SLC26A1—nephrolithiasis	0.000125	0.00521	CbGpPWpGaD
Topiramate—CA5A—Metabolism—APRT—nephrolithiasis	0.000125	0.00521	CbGpPWpGaD
Topiramate—CA6—Metabolism—APRT—nephrolithiasis	0.000125	0.00521	CbGpPWpGaD
Topiramate—CA5A—Metabolism—SLC26A1—nephrolithiasis	0.000125	0.00521	CbGpPWpGaD
Topiramate—CA5B—Metabolism—SLC26A1—nephrolithiasis	0.000117	0.00486	CbGpPWpGaD
Topiramate—CA7—Metabolism—APRT—nephrolithiasis	0.000117	0.00486	CbGpPWpGaD
Topiramate—CA5B—Metabolism—APRT—nephrolithiasis	0.000117	0.00486	CbGpPWpGaD
Topiramate—CA7—Metabolism—SLC26A1—nephrolithiasis	0.000117	0.00486	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000115	0.00479	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000115	0.00479	CbGpPWpGaD
Topiramate—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.000114	0.00475	CbGpPWpGaD
Topiramate—CA4—Metabolism—GRHPR—nephrolithiasis	0.000114	0.00474	CbGpPWpGaD
Topiramate—CA2—Metabolism—GRHPR—nephrolithiasis	0.000109	0.00455	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000109	0.00454	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000109	0.00454	CbGpPWpGaD
Topiramate—CA12—Metabolism—APRT—nephrolithiasis	0.000108	0.00451	CbGpPWpGaD
Topiramate—CA12—Metabolism—SLC26A1—nephrolithiasis	0.000108	0.00451	CbGpPWpGaD
Topiramate—CA1—Metabolism—GRHPR—nephrolithiasis	0.000104	0.00436	CbGpPWpGaD
Topiramate—CA4—Metabolism—AGXT—nephrolithiasis	0.000101	0.00423	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000101	0.00422	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000101	0.00422	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	9.96e-05	0.00416	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	9.96e-05	0.00416	CbGpPWpGaD
Topiramate—CA2—Metabolism—AGXT—nephrolithiasis	9.71e-05	0.00405	CbGpPWpGaD
Topiramate—CA1—Metabolism—AGXT—nephrolithiasis	9.31e-05	0.00388	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	9.26e-05	0.00386	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	9.26e-05	0.00386	CbGpPWpGaD
Topiramate—CA9—Metabolism—GRHPR—nephrolithiasis	9.18e-05	0.00383	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	9.03e-05	0.00377	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	9.03e-05	0.00377	CbGpPWpGaD
Topiramate—CA5A—Metabolism—AQP1—nephrolithiasis	8.9e-05	0.00371	CbGpPWpGaD
Topiramate—CA6—Metabolism—AQP1—nephrolithiasis	8.9e-05	0.00371	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	8.71e-05	0.00363	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	8.71e-05	0.00363	CbGpPWpGaD
Topiramate—CA4—Metabolism—APRT—nephrolithiasis	8.61e-05	0.00359	CbGpPWpGaD
Topiramate—CA4—Metabolism—SLC26A1—nephrolithiasis	8.61e-05	0.00359	CbGpPWpGaD
Topiramate—CA7—Metabolism—AQP1—nephrolithiasis	8.31e-05	0.00347	CbGpPWpGaD
Topiramate—CA5B—Metabolism—AQP1—nephrolithiasis	8.31e-05	0.00347	CbGpPWpGaD
Topiramate—CA2—Metabolism—SLC26A1—nephrolithiasis	8.26e-05	0.00344	CbGpPWpGaD
Topiramate—CA2—Metabolism—APRT—nephrolithiasis	8.26e-05	0.00344	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	8.26e-05	0.00344	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	8.26e-05	0.00344	CbGpPWpGaD
Topiramate—CA9—Metabolism—AGXT—nephrolithiasis	8.19e-05	0.00341	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	8.1e-05	0.00338	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	8.1e-05	0.00338	CbGpPWpGaD
Topiramate—CA5A—Metabolism—CHRM3—nephrolithiasis	8.05e-05	0.00336	CbGpPWpGaD
Topiramate—CA6—Metabolism—CHRM3—nephrolithiasis	8.05e-05	0.00336	CbGpPWpGaD
Topiramate—CA1—Metabolism—APRT—nephrolithiasis	7.92e-05	0.0033	CbGpPWpGaD
Topiramate—CA1—Metabolism—SLC26A1—nephrolithiasis	7.92e-05	0.0033	CbGpPWpGaD
Topiramate—CA12—Metabolism—AQP1—nephrolithiasis	7.7e-05	0.00321	CbGpPWpGaD
Topiramate—CA7—Metabolism—CHRM3—nephrolithiasis	7.51e-05	0.00313	CbGpPWpGaD
Topiramate—CA5B—Metabolism—CHRM3—nephrolithiasis	7.51e-05	0.00313	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	7.22e-05	0.00301	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	7.22e-05	0.00301	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	7.22e-05	0.00301	CbGpPWpGaD
Topiramate—CA9—Metabolism—SLC26A1—nephrolithiasis	6.96e-05	0.0029	CbGpPWpGaD
Topiramate—CA12—Metabolism—CHRM3—nephrolithiasis	6.96e-05	0.0029	CbGpPWpGaD
Topiramate—CA9—Metabolism—APRT—nephrolithiasis	6.96e-05	0.0029	CbGpPWpGaD
Topiramate—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	6.85e-05	0.00286	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	6.6e-05	0.00275	CbGpPWpGaD
Topiramate—CA4—Metabolism—AQP1—nephrolithiasis	6.14e-05	0.00256	CbGpPWpGaD
Topiramate—CA2—Metabolism—AQP1—nephrolithiasis	5.88e-05	0.00245	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	5.77e-05	0.00241	CbGpPWpGaD
Topiramate—CA1—Metabolism—AQP1—nephrolithiasis	5.64e-05	0.00235	CbGpPWpGaD
Topiramate—CA4—Metabolism—CHRM3—nephrolithiasis	5.55e-05	0.00232	CbGpPWpGaD
Topiramate—CA2—Metabolism—CHRM3—nephrolithiasis	5.32e-05	0.00222	CbGpPWpGaD
Topiramate—CA1—Metabolism—CHRM3—nephrolithiasis	5.1e-05	0.00213	CbGpPWpGaD
Topiramate—CA9—Metabolism—AQP1—nephrolithiasis	4.96e-05	0.00207	CbGpPWpGaD
Topiramate—CA9—Metabolism—CHRM3—nephrolithiasis	4.49e-05	0.00187	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GRHPR—nephrolithiasis	2.57e-05	0.00107	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—AGXT—nephrolithiasis	2.29e-05	0.000956	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—APRT—nephrolithiasis	1.95e-05	0.000813	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	1.95e-05	0.000813	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GRHPR—nephrolithiasis	1.55e-05	0.000645	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—AQP1—nephrolithiasis	1.39e-05	0.000579	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—AGXT—nephrolithiasis	1.38e-05	0.000575	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—CHRM3—nephrolithiasis	1.26e-05	0.000524	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—APRT—nephrolithiasis	1.17e-05	0.000489	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	1.17e-05	0.000489	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—AQP1—nephrolithiasis	8.35e-06	0.000348	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—CHRM3—nephrolithiasis	7.55e-06	0.000315	CbGpPWpGaD
